Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. PDL BioPharma's annualizedGross Profit for the quarter that ended in Jun. 2020 was $10.29 Mil.
PDL BioPharma's average Total Assets over the quarter that ended in Jun. 2020 was $590.23 Mil. Therefore, PDL BioPharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2020 was 1.74%.
PDL BioPharma Gross-Profit-to-Asset % Historical Data
The historical data trend for PDL BioPharma's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDL BioPharma's Gross-Profit-to-Asset %
For the Biotechnology subindustry, PDL BioPharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDL BioPharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDL BioPharma's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where PDL BioPharma's Gross-Profit-to-Asset % falls into.
PDL BioPharma Gross-Profit-to-Asset % Calculation
PDL BioPharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2019 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Jun. 2020) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
PDL BioPharma Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of PDL BioPharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
PDL BioPharma (PDL BioPharma) Business Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDLI has been successfully added to your 